EUDA Health Holdings Limited (EUDA) Key Metrics
EUDA valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $46.1M
- Enterprise value
- $53.9M
- P/E (TTM)
- —
- Forward P/E
- 7.8
- PEG ratio
- —
- Price / sales
- 6.4 10-yr median 10.7
- Price / book
- —
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.59
EUDA key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsEUDA valuation Price multiples at each fiscal year-end price.
Price / sales−65.2%
12.6
2025 · hover or tap a bar for each year
20202025
Free cash flow yield−1.5 pts
−2.9%
2025 · hover or tap a bar for each year
20202025
EUDA returns How much profit the business earns on the capital it uses.
Return on assets
−160.9%
2025 · hover or tap a bar for each year
20202025
Free cash flow margin+16.5 pts
−37.1%
2025 · hover or tap a bar for each year
20202025
Asset turnover+50.0%
3.96
2025 · hover or tap a bar for each year
20202025
EUDA per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+48.5%
$3.67
2025 · hover or tap a bar for each year
20202025
Earnings per share
−$1.49
2025 · hover or tap a bar for each year
20202025
Free cash flow per share
−$1.36
2025 · hover or tap a bar for each year
20202025
Book value per share
−$2.29
2025 · hover or tap a bar for each year
20202025
Shares outstanding+14.5%
1.9M
2025 · hover or tap a bar for each year
20202025
EUDA financial health Debt, liquidity and how easily interest is covered.
Net debt+$1.0M
$2.1M
2025 · hover or tap a bar for each year
20202025
Current ratio−3.3%
0.18
2025 · hover or tap a bar for each year
20202025
Interest coverage
-10.7
2025 · hover or tap a bar for each year
20202025
Debt / assets+90.1%
1.40
2025 · hover or tap a bar for each year
20202025
EUDA efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−5 days
13 days
2025 · hover or tap a bar for each year
20202025
Days of inventory−1 days
6 days
2025 · hover or tap a bar for each year
20202025
Days payables outstanding0 days
2 days
2025 · hover or tap a bar for each year
20202025
Cash conversion cycle−6 days
18 days
2025 · hover or tap a bar for each year
20202025
Capex / revenue−1.4 pts
1.5%
2025 · hover or tap a bar for each year
20202025
EUDA valuation history
Fiscal year-endToday6-year median
EUDA returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
EUDA debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
EUDA cash returned to shareholders
DividendsBuybacksFree cash flow
EUDA price vs earnings per share
Share price at year-endEPS (right axis)
EUDA key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $85.8M | $145.3M | $32.7M | $19.8M | — | — |
| Enterprise value | $87.9M | $146.3M | $35.9M | $23.4M | — | — |
| Price / sales | 12.6 | 36.2 | 8.8 | 5.3 | — | — |
| EV / sales | 12.9 | 36.5 | 9.7 | 6.2 | — | — |
| Earnings yield | −3.2% | −10.6% | −30.7% | −125.5% | — | — |
| Free cash flow yield | −2.9% | −1.5% | −8.9% | −7.8% | — | — |
| Dividend yield | — | — | — | 6.6% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 13.2% | — | — |
| Share price at fiscal year-end | $46.20 | $89.50 | $28.60 | $32.95 | $195.00 | — |
| Per share | ||||||
| Revenue per share | $3.67 | $2.47 | $3.24 | $6.26 | — | — |
| Earnings per share | −$1.49 | −$9.46 | −$8.77 | −$41.37 | — | — |
| Operating cash flow per share | −$1.31 | −$1.25 | −$2.55 | −$2.54 | — | — |
| Free cash flow per share | −$1.36 | −$1.33 | −$2.55 | −$2.57 | — | — |
| Cash per share | $0.19 | $0.15 | $0.17 | $0.10 | — | — |
| Book value per share | −$2.29 | −$1.57 | −$6.55 | −$5.85 | — | — |
| Tangible book value per share | −$2.38 | −$1.78 | −$6.55 | −$5.85 | — | — |
| Dividends per share | — | — | — | $2.17 | — | — |
| Capex per share | $0.06 | $0.07 | $0.00 | $0.03 | — | — |
| Debt per share | $1.29 | $0.78 | $2.95 | $6.04 | — | — |
| Shares outstanding | 1.9M | 1.6M | 1.1M | 601K | — | — |
| Change in shares outstanding | +14.5% | +41.7% | +90.4% | — | — | — |
| Returns & profitability | ||||||
| Return on invested capital (ROIC) | — | — | — | — | −122.0% | −731.6% |
| Return on assets (ROA) | −160.9% | — | −74.5% | −148.0% | 12.5% | 3.0% |
| Return on tangible assets | −178.3% | — | −766.1% | −97.1% | 12.9% | 4.0% |
| Free cash flow margin | −37.1% | −53.6% | −78.7% | −41.0% | 9.7% | −5.5% |
| Income quality (OCF / net income) | — | — | — | — | 0.51 | −2.35 |
| Financial health | ||||||
| Total debt | $2.4M | $1.3M | $3.4M | $3.6M | $462,306 | $709,966 |
| Cash & short-term investments | $345,145 | $237,605 | $189,005 | $57,541 | $189,996 | $250,767 |
| Net debt | $2.1M | $1.0M | $3.2M | $3.6M | $272,310 | $459,199 |
| Debt / equity | — | — | — | — | 0.89 | — |
| Debt / assets | 1.40 | 0.74 | 2.57 | 0.14 | 0.06 | 0.12 |
| Net debt / EBITDA | — | — | — | — | 0.20 | — |
| Current ratio | 0.18 | 0.18 | 0.08 | 0.86 | 0.59 | 0.70 |
| Quick ratio | 0.18 | 0.15 | 0.08 | 0.84 | 0.59 | 1.09 |
| Interest coverage | -10.7 | -386.2 | -170.6 | -61.0 | -4.4 | -13.6 |
| Working capital | −$4.8M | −$3.4M | −$8.0M | −$4.1M | −$3.0M | −$1.8M |
| Invested capital | −$2.2M | −$1.5M | −$4.3M | $52,850 | $793,542 | $98,610 |
| Tangible asset value | −$4.4M | −$2.9M | −$7.5M | −$3.5M | −$682,598 | −$1.8M |
| Net current asset value | −$4.9M | −$3.5M | −$8.1M | −$4.1M | −$3.0M | −$1.9M |
| Graham net-net per share | −$2.90 | −$2.39 | −$7.36 | −$47.57 | — | — |
| Capital allocation | ||||||
| Dividends paid | — | — | — | $1.3M | — | — |
| Share buybacks (net) | — | — | — | $1.3M | — | — |
| Capex / revenue | 1.5% | 2.9% | 0.0% | 0.5% | 0.0% | 0.9% |
| Capex / operating cash flow | — | — | — | — | 0.4% | — |
| Capex / depreciation | 0.26 | 0.67 | 0.00 | 0.11 | 0.01 | 0.27 |
| Stock-based compensation / revenue | — | — | — | 5.9% | — | — |
| R&D / revenue | 0.0% | — | — | 0.5% | 2.8% | 1.8% |
| SG&A / revenue | 79.7% | 83.3% | 129.6% | 179.3% | 32.4% | 52.1% |
| Efficiency | ||||||
| Days sales outstanding | 13.5 | 18.6 | 21.3 | 207.6 | 228.3 | 66.4 |
| Days of inventory on hand | 6.3 | 7.2 | — | 81.7 | — | -171.8 |
| Days payables outstanding | 1.9 | 1.5 | 93.2 | 269.9 | 237.0 | 108.1 |
| Cash conversion cycle (days) | 17.9 | 24.3 | -30.6 | 19.4 | -8.6 | -213.6 |
| Receivables turnover | 27.04 | 19.59 | 17.16 | 1.76 | 1.60 | 5.50 |
| Payables turnover | 191.22 | 239.13 | 3.92 | 1.35 | 1.54 | 3.38 |
| Inventory turnover | 58.07 | 50.38 | — | 4.47 | — | — |
| Asset turnover | 3.96 | 2.64 | 0.28 | 0.22 | 0.66 | 1.51 |
| Average receivables | $252,234 | $204,726 | $216,018 | $2.1M | $2.9M | $1.6M |
| Average payables | $20,016 | $13,587 | $731,373 | $2.1M | $2.1M | $1.5M |
| Average inventory | $65,910 | $64,488 | $324,078 | $648,156 | — | −$2.3M |
| Intangibles / total assets | 9.4% | 19.5% | 0.0% | 0.0% | 16.0% | 25.1% |
Computed from EUDA's annual financial statements (latest annual report filed April 28, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
EUDA valuation and financial ratios
It ended the year with $2.4 million of debt and $0.3 million in cash and short-term investments, net debt of $2.1 million.
See the EUDA income statement, the EUDA chart for price history, or the EUDA stock overview for the latest quote and news.
EUDA key metrics FAQ
How much debt does EUDA Health have?
EUDA Health had total debt of $2.4 million at the end of fiscal 2025.
What is EUDA Health's free cash flow yield?
EUDA Health generated -$2.5 million of free cash flow in fiscal 2025, a free cash flow yield of −2.9% on its market value at year-end ($85.8 million).
What is EUDA Health's current ratio?
EUDA Health's current ratio was 0.18 at the end of fiscal 2025: current assets were 0.18 times current liabilities.